title: NICE guidance on olaparib for maintenance treatment of patients with relapsed, platinum-sensitive, BRCA mutation-positive ovarian cancer.
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK. Electronic address: helen.tucker@nice.org.uk.
authors.forename: Helen
authors.initials: H
authors.lastname: Tucker
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Zoe
authors.initials: Z
authors.lastname: Charles
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Janet
authors.initials: J
authors.lastname: Robertson
authors.affiliation: National Institute for Health and Care Excellence, London SW1A 2BU, UK.
authors.forename: Jane
authors.initials: J
authors.lastname: Adam
mesh_terms: D061605:Administration, Intravenous; D000368:Aged; D016190:Carboplatin / Q000009:adverse effects / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D019398:Genes, BRCA1; D018095:Germ-Line Mutation; D006801:Humans; D060046:Maintenance Chemotherapy; D008875:Middle Aged; D009361:Neoplasm Invasiveness / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality / Q000473:pathology; D010793:Phthalazines / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016019:Survival Analysis; D006113:United Kingdom
chemical_list: D010793:Phthalazines; D010879:Piperazines; D016190:Carboplatin; C531550:olaparib